top of page
  • Writer's pictureEVOCAL Health

Health-i Award 2021: EVOCAL Health nominated as one of the Top 5 Most Innovative Health Companies

EVOCAL health shortlisted as one of the most innovative health startups in Germany in the Health-i-Award from Handelsblatt and Techniker Krankenkasse

Hamburg (Germany), September 8, 2021: EVOCAL Health, a biopharmaceutical digital health company unlocking the human voice as a biomarker for AI-based detection and treatment of diseases (so-called vocal biomarkers), today announced to be selected as one of the “Top 5 Most Innovative Healthcare Companies in Germany” (category: start-up companies) by the German business newspaper Handelsblatt and the health insurance company Techniker Krankenkasse for the Health-i Award.

The “Health-i Award” is one of the most prestigious awards for upstarting healthcare companies in Germany offering an excellent network and visibility for digital innovation drivers and disruptive technologies. With over 200 applicants, experts from Techniker Krankenkasse, Handelsblatt, and scientific partners of the Handelsblatt Media Group had to shortlist and select the Top 15 healthcare companies in Germany across different company stages, that research and develop meaningful digital health and life science innovations and are striving to become a natural part of medical care. Also, criteria such as competence, market attractiveness, unique selling proposition, and financing among others had to be met.

EVOCAL Health convinced the jury with their technology using AI and vocal biomarkers to detect and treat diseases. “We feel very honored and grateful, to be selected for Health-i Award 2021. The nominated companies are turning science fiction into science reality, and we are thankful that Handelsblatt Media Group and Techniker Krankenkasse are providing this platform that highlights innovation and science, and are delighted that our work of unlocking the human voice as a biomarker has been acknowledged by the experts”, says EVOCAL Health Co-Founder & CEO/COO Philip Mertes.

bottom of page